AVNS:NYE-Avanos Medical Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 32.84

Change

0.00 (0.00)%

Market Cap

USD 1.58B

Volume

0.22M

Avg Analyst Target

USD 44.33 (+35.00%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia. Address: 5405 Windward Parkway, Alpharetta, GA, United States, 30004

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

N/A

USD208.29B 33.10 19.31
MDT Medtronic plc

N/A

USD171.93B 44.68 23.47
SYK Stryker Corporation

N/A

USD100.43B 48.80 28.11
EW Edwards Lifesciences Corporati..

N/A

USD69.91B 48.68 51.82
BSX Boston Scientific Corporation

N/A

USD61.80B 117.62 33.26
ZBH Zimmer Biomet Holdings Inc

N/A

USD30.57B 33.34 17.38
STE STERIS plc

N/A

USD22.45B 68.67 37.18
BIO-B Bio-Rad Laboratories Inc

N/A

USD21.56B 5.51 3.83
BIO Bio-Rad Laboratories Inc

N/A

USD21.56B 5.38 3.83
SNN Smith & Nephew plc

N/A

USD15.56B 28.09 14.43

ETFs Containing AVNS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.42% 17% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.42% 17% F 6% F
Trailing 12 Months  
Capital Gain -13.90% 25% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.90% 25% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.91% 8% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.91% 8% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 30.37% 54% F 37% F
Risk Adjusted Return -6.28% 8% F 10% F
Market Capitalization 1.58B 35% F 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 821.00 6% F 1% F
Price/Book Ratio 1.18 92% A- 68% D+
Price / Cash Flow Ratio -632.15 96% A 98% A+
EV/EBITDA 62.32 10% F 7% F
Management Effectiveness  
Return on Equity 0.19% 38% F 28% F
Return on Invested Capital -0.87% 41% F 24% F
Return on Assets 0.50% 33% F 22% F
Debt to Equity Ratio 14.33% 73% C 83% B
Technical Ratios  
Short Ratio 3.26 58% F 36% F
Short Percent 2.60% 52% F 54% F
Beta 0.90 58% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector